OurWarOnCancer

Tell Congress to fund #OurWarOnCancer & devote the same tax dollars 2 fighting this enemy that we would 2 fight any other enemy killing 600,000 Americans/yr!

[OurWarOnCancer @OurWarOnCancer]

We have a @WhiteHouse & @POTUS & @VP who support #CancerResearch & know all too well the struggles of cancer patients & families. Take a minute a write to them & other reps & tell your story & push 4 more cancer research funding https://t.co/givJJIXQRA

[IASLC @IASLC]

🎧 New Lung Cancer Considered episode

In Part 1 of our @ASCO 2026 Highlights series, @NarjustFlorezMD and @StephenVLiu are joined by Dr. Jonathan Goldman and Dr. Alice Shaw to discuss practice-changing data in #NSCLC, including LIBRETTO-432, #ALK-positive disease outcomes, and new #EGFR exon 20 insights. Listen now: https://t.co/oDCl3882No

#LungCancer #LungCancerConsidered #ASCO26

[Mario Balsa @MarioBalsaMD]

👋🏼 After covering my #ASCO26 Top 10 melanoma studies, one thing feels clear: the future is personal!!!!
🎯 Personalized vaccines
🎯 Next-generation TILs
🎯 PRAME-targeted TCR therapies
🎯 Smarter neoadjuvant IO

Different approaches. Same goal: helping more patients live longer and better.

Thank you to the amazing @OncoAlert community, and especially to @weoncologists for the mentorship, inspiration, and countless lessons along the way 🙏

I came to #ASCO26 looking for answers. I’m leaving with even better melanoma questions 🖤

The science was inspiring…but people behind it even more @OncoAlert 📡

@DrChoueiri 🇺🇸
@hoperugo 🇺🇸
@matteolambe 🇮🇹
@TiansterZhang 🇺🇸
@CathyEngMD 🇺🇸
@stolaney1 🇺🇸
@montypal 🇺🇸
@tompowles1 🇬🇧
@brian_rini 🇺🇸
@cdanicas 🇪🇸
@NiuSanford 🇺🇸
@amerseburger 🇩🇪
@GlopesMd 🇺🇸
@Icro_Meattini 🇮🇹
@PGrivasMDPhD 🇺🇸
@DrYukselUrun 🇹🇷
@nataliagandur 🇦🇷
@ElisaAgostinett 🇧🇪
@HHorinouchi 🇯🇵
@realbowtiedoc 🇺🇸
@to_be_elizabeth 🇮🇹
@UOzkerim 🇹🇷
@p_ciracimd 🇮🇹
@DrVilmaPBarcia 🇪🇸
@DraMartinezLago 🇪🇸
@DrMirallas 🇺🇸
@GaiaGriguolo 🇮🇹
@scocmem 🇬🇧
@AmandaNizamMD 🇺🇸
& @weoncologists 🇺🇸

[Dr. Catharine Young @DrCatharineY]

A cancer vaccine, using the same core mRNA technology as the COVID vaccine, has shown an almost 50% reduction in the risk of melanoma recurrence or death when combined with immunotherapy.

This is why we fund MRNA technology.

[Dr. Estela Rodriguez @Latinamd]

Here are my own #ASCO26 Top 10 🫁 Lung Cancer Abstracts based on potential clinical impact — although there is so much exciting and innovative science being presented across the field. Looking forward to the discussions, debates, and future directions these data may inspire. #LungCancer

[David Gandara @drgandara]

#ASCO Living Guideline in NSCLC. Thanks @HHorinouchi for posting. By far the most transparent. Practicing Oncologists need to know what is strongly endorsed, not just a laundry list of every approved regimen. Bravo ASCO! @ASCO

[Lung Cancer Research Foundation @lcrf_org]

Are you going to the ASCO Annual Meeting in Chicago? LCRF will be there this weekend! Visit us at the ASCO-Sponsored Patient Advocacy Booth (#13000) from May 30 - June 1. We'd love to share our #LungCancer resources and information with you.

[Uğur Özkerim @UOzkerim]

✅ Some NSCLC subgroups continue to challenge our current immunotherapy strategies more than others.

At #ASCO26, the TRITON study explores whether adding anti-CTLA-4 can improve outcomes in STK11-, KEAP1-, and KRAS-mutated nonsquamous mNSCLC — a population often associated with poorer IO outcomes.

The ORR difference may look modest, but the durability-of-response signal appears meaningful.

Perhaps the future of immunotherapy is not “more IO for everyone,” but smarter IO for biologically selected patients.

@OncoAlert @weoncologists @OncoReporte @MedwatchKate @tugbawitter @OncBrothers @brunolarvol @GlopesMd @ASCO
@StephenVLiu
@peters_solange
@CharuAggarwalMD
@MartinReck2
@christine_lovly
@DrMirallas
@bmassutis @UmbertoMalapel1
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

[Uğur Özkerim @UOzkerim]

My personal lung cancer highlights to watch at #ASCO2026 🫁🔥

A very exciting year for thoracic oncology — from perioperative strategies and next-generation ADCs to RET/ALK advances and emerging SCLC data.
@OncoAlert @MedwatchKate @OncoReporte @JCOGO_ASCO @ASCO @LungCancerRx @LungCancerEu @tugbawitter @weoncologists @GlopesMd @Larvol @brunolarvol

[Stephen V Liu, MD @StephenVLiu]

Very helpful overview of ivonescimab at #RomeLung26 from @GautschiOliver - eagerly awaiting OS results from HARMONi-6 at #ASCO26.

[Anirban Maitra @Aiims1742]

New @Cancer_Cell paper on mechanisms of resistance to @RevMedicines Daraxonrasib
Disrupted molecular glue complex drives RAS inhibitor resistance
https://t.co/lFzq41ki8p
18/40 genomic alterations in RAS pathway (👇🏽)
Recurrent RAS Y64 alteration attenuates tri-complex formation

[Mukund Iyengar @mukundiyngr]

Every cancer drug you prescribe today
was once an NIH grant nobody noticed.

Pharma celebrates launches.

Few notice the 20–40 year runway behind that.

Gleevec took 41 years from NIH-funded discovery of the Philadelphia chromosome → FDA approval.

Behind every “breakthrough” sits a graveyard of failed attempts that made it possible.

Cut that lineage today,
the next Gleevec doesn’t arrive in 2067.

Funded science matters.

If someone says NIH funded science is inefficient,
show them this.

- - - - -
Source: NIH RePORTER · FDA · via @Jori_health
- - - - -

[Stephen V Liu, MD @StephenVLiu]

Massive amount of updates in KRAS at #RomeLung26 from Dr. @FSkoulidis - two G12C inhibitors approved, next gen agents overcoming resistance, potential role earlier with front line combinations. Excitement for early stage role. And recent gains in G12D and pan-(K)RAS inhibitors.

[Dr. Tom Frieden @DrTomFrieden]

Two rigorous new studies reach the same conclusion: delaying the hepatitis B birth dose means hundreds more infant infections, more liver cancer, more deaths, and millions of dollars in added costs. The evidence for the birth dose has always been strong. These studies make it even stronger.

[David Gandara @drgandara]

Not so sure that HER2 mutation should be called EGFR's poor sister any more. This poor sister is going to the prom as Queen, with her dancing shoes on! 💃

[Eric K. Singhi, MD @lungoncdoc]

Congratulations to @drshieldsmd & the @LUNGevity Foundation on a successful inaugural @SclcSMASHERS LIVE!

Thanks for the invite to chat with patients & their care partners about the most recent treatment advancements in this space!

[Stephen V Liu, MD @StephenVLiu]

Inaugural US Focus Meeting on Lung Cancer from @_MDEducation starts in Nashville with EGFR session. Great overviews by Drs. @LeXiuning Liza Villaruz @ZPiotrowskaMDand panel chaired by @CharuAggarwalMD. Great areas for discussion including LCT, bispecifics, and ADCs.

[Balazs Halmos @BalazsHalmosMD]

Congrats on a first US Focus Meeting on Lung Cancer where @CharuAggarwalMD and @StephenVLiu got just the right pieces together to build a great event- including a Monte mini-reunion in Honky-Tonk town
@Shuai_WangOnc @HyeinJeon_MD

[Brendon Stiles @BrendonStilesMD]

Well...he's not wrong.

But immunotherapy likely overcomes some problems of "targeted" therapy.

And the same resistance pathways active in some of these tumors may also cause resistance to RT (😉).

But many too often ignore the power of local therapy to contribute to cure.

[Hidehito HORINOUCHI @HHorinouchi]

🔥Lung cancer brain mets at the dawn of personalized medicine
🆙 @Annals_Oncology @myESMO
🎯Emerging systemic therapies show growing intracranial efficacy
🎙Dr. Antoine Mavrikios @finn_corinne
#LCSM @OncoAlert @Larvol
https://t.co/aPNOdmgJlJ

[Anirban Maitra @Aiims1742]

Expanded access - while very welcome - is a lot of paperwork. Daraxonrasib needs to be approved so it can be used without delay by patients with metastatic #PancreaticCancer who have progressed on prior therapy.
There is a national priority voucher - what are we waiting for?